Phase 2 Momelotinib Trial: JAK1/JAK2 inhibitor for low-risk MDS anemia

This trial evaluates different momelotinib doses to optimize treatment safety, pharmacokinetics, and efficacy in reducing red blood cell transfusion needs for patients with low-risk myelodysplastic syndrome (LR-MDS) and anemia refractory or intolerant to existing agents. Conducted by GlaxoSmithKline, the study employs a two-part design where the dose-finding phase informs an expansion phase to confirm the optimal dose for targeted JAK1 and JAK2 inhibition.